Federal courts have intervened to halt sweeping workforce reductions and reorganization plans at the U.S. Department of Health and Human Services (HHS), citing likely unlawful actions impacting thousands of employees. These injunctions come amid lawsuits filed by multiple states and employee groups contesting extensive layoffs and structural overhauls. Additionally, regulatory scrutiny intensifies for companies like Pfizer regarding vaccine approval processes, while new legal and policy debates emerge around pharmaceutical pricing and authorization frameworks, reflecting heightened oversight in the biotech sector.